

September 12, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our communication dated July 23, 2026, regarding the acquisition of the A1 Biochem Group, this is to inform you that A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company has subscribed to 10,000 equity shares of USD 100 (Hundred Only) each of 'A1 Biochem USA Inc' in USA on September 11, 2026.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as '**Annexure A**'.

This is for your information and records.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: Annexure A

(CIN : L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED
www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure -A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Name: A1 Biochem USA Inc Turnover: Not applicable as the company is yet to commence business
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length";	A1 Biochem USA Inc is a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited. A1 Biochem Labs India Private Limited is a subsidiary of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company and therefore is a related party of the Company. Promoters and promoter group of the Company are not interested in the transaction
c) Industry to which the business of the target entity being acquired belongs;	Pharmaceuticals
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The object of this subsidiary is to undertake the Contract Research and Development services business as part of the acquisition of A1 Biochem Group earlier disclosed on July 23, 2026.
e) Brief details of any governmental or regulatory approvals required for the acquisition.	No governmental or regulatory approvals required.
f) Indicative time period for completion of the acquisition.	Not applicable
g) Nature of consideration - whether cash consideration or share swap or any other form and details of the same;	100% subscription to the share capital in cash
h) Cost of acquisition and / or the price at which the shares are acquired; New Subsidiary was incorporated.	The Company has subscribed to the Initial subscription share capital of USD 1,000,000 on September 11, 2026 divided into 10,000 equity shares of USD 100 each.
i) Percentage of shareholding / control acquired and or number of shares acquired;	100%
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	This is a newly incorporated company and therefore the history of the last 3 years' turnover is not available. This company shall be carrying out Contract Research and Development services business from USA A1 Biochem USA Inc was incorporated on August 27, 2026 in USA

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com